Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MirrorBody

Financiado

Discovery, total chemical synthesis, and validation of mirror-image D-Nanobodies

The central role of molecularly-targeted therapeutics and imaging probes in translational research entails the development of an ever-growing arsenal of chemical biologics endowed with optimal in vivo properties. In this regard, m... ver más

31/07/2024

CNRS

196K€

Presupuesto del proyecto: 196K€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-07-31

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100%

1 Participantes

CNRS

195.91K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CPP2021-008924 NUEVOS CONJUGADOS ANTICUERPO-FÁRMACO BIESPECÍFICOS BASADOS E... 751K€ Cerrado

OVCure Curing ovarian cancer through autoantibody-based therapy 150K€ Cerrado

LEGO Multimodal glycoconjugates a molecular Lego approach for an... 2M€ Cerrado

CTQ2015-71506-R CONJUGACION DE MACROLIDOS CON ANTICUERPOS Y DE INHIBIDORES D... 151K€ Cerrado

RTC-2017-5944-1 ATTACK- Inmunoterapia del cáncer mediante anticuerpos biespe... 332K€ Cerrado

AB-AG-INTERACT Learning the interaction rules of antibody-antigen binding 2M€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2022-07-08
Fecha Fin: 2024-07-31

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 196K€

Descripción del proyecto The central role of molecularly-targeted therapeutics and imaging probes in translational research entails the development of an ever-growing arsenal of chemical biologics endowed with optimal in vivo properties. In this regard, mAbs and their derivatives (e.g. ADCs) still suffer from unsettled drawbacks involving difficulties in production and characterization, leading to heterogeneous conjugates in terms of size, potency and toxicity. Chemical modifications on mAbs are highly unreliable due to their complex structure: a central problem in this discipline, where heterogeneous drug-to-antibody ratio (DAR) and conjugation site represent significative limitations. Immunogenicity is a major drawback which affects humanized, as well as fully-human mAbs, and is exacerbated by long half-lives. Cases of unwanted activation of the immune system reportedly degenerated to life-threatening conditions such as acute anaphylaxis, serum sickness and cytokine release syndrome. Their bulky size (≈150 kDa) hinders their extravasation, impairing their efficiency to enter tumors. Nanobodies (Nbs) are the smallest naturally-derived antibody fragments (≈13-14 kDa) that retain antigen-binding affinities in the same range of mAbs (nM to pM affinity range) while having extremely reduced half-lives ( ≈ 15 min.) when not bound to their target, thanks to a fast renal excretion. MirrorBody intends to push the boundaries of targeted chemical biologics via an interdisciplinary approach that exploits both immunology and synthetic chemistry techniques for the generation of synthetic D-nanobodies that bind natural L-targets with high affinity. Such unprecedented synthetic D-Nbs will be endowed with improved biocompatibility, and will enable plug-and-play approaches for the controlled conjugation of diverse moieties.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores